Clinical Trials Directory

Trials / Completed

CompletedNCT05086445

A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus

A Single- and Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
62 (actual)
Sponsor
Eli Lilly and Company · Industry
Sex
All
Age
20 Years – 70 Years
Healthy volunteers
Not accepted

Summary

The main purpose of this study is to learn about the side effects of LY3502970 when given to Japanese participants with type 2 diabetes mellitus (T2DM). Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant, the study will last up to 24 weeks, inclusive of screening and will include 10 visits to the study center.

Conditions

Interventions

TypeNameDescription
DRUGLY3502970Administered orally
DRUGPlaceboAdministered orally

Timeline

Start date
2021-11-12
Primary completion
2022-09-05
Completion
2022-09-05
First posted
2021-10-21
Last updated
2022-11-28

Locations

5 sites across 1 country: Japan

Source: ClinicalTrials.gov record NCT05086445. Inclusion in this directory is not an endorsement.